Similar articles

Abstract: Objective: To quantify the changes in blood glucose, blood lipids, blood pressure, and the intima-media thickness (IMT) of large arteries in patients with new-onset type 2 diabetes mellitus who received either intensive multifactorial treatment or conventional treatment. Methods: Two-hundred and ten patients with new-onset type 2 diabetes mellitus were randomly assigned to two groups: an intensive treatment group (n=110) and a conventional treatment group (n=100). Fasting blood glucose (FBG), glycosylated hemoglobin A1c (HbA1c), blood pressure, blood lipids [total cholesterol (TC), triglyceride (TG), low-density lipoprotein C (LDL-C), and high-density lipoprotein C (HDL-C)], and IMTs of large arteries (carotid, iliac, and femoral arteries) were determined before and at one and two years after starting treatment. The patients in the conventional treatment group received routine diabetes management in our outpatient department. Targets were established for patients in the intensive treatment group. Their blood glucose, blood lipids, and blood pressure levels were regularly monitored and therapeutic regimens were adjusted for those whose measurements did not meet the target values until all the parameters met the established targets. Within-group and between-group differences were evaluated. Results: A significantly greater percentage of patients in the intensive treatment group had LDL-C levels that reached the target value one year after starting treatment than those in the conventional treatment group (52.04% vs. 33.33%, P<0.05). No significant differences were found between groups for FBG, HbA1c, blood pressure, TG, TC, or HDL-C. The percentages of patients with TG (51.02% vs. 34.48%), TC (52.04% vs. 33.33%), and LDL-C (61.22% vs. 43.67%) who met the respective target values in the intensive treatment group were all significantly higher than the corresponding percentages in the conventional treatment group two years after starting treatment (P<0.05). There were no significant differences in the percentages of patients with FBG, HbA1c, and blood pressure values meeting the respective targets between the groups at the two-year follow-up. One year after starting treatment, the LDL-C level, diastolic blood pressure (DBP), and the IMTs of the femoral and iliac arteries of the intensive treatment group were significantly lower compared to those of the conventional treatment group (P<0.05), although there was no significant difference in other metabolic parameters. Two years after starting treatment, the TC, LDL-C, blood pressure [systolic blood pressure (SBP) and DBP], and the IMTs of the carotid and femoral arteries of the intensive treatment group were significantly lower than those of the conventional treatment group (P<0.05). No significant differences in other metabolic parameters existed between the two groups two years after starting treatment. Conclusions: Early comprehensive and intensive treatment of type 2 diabetes mellitus can delay or even reverse the increase in IMT of large arteries. Lowering blood pressure and blood lipid regulation in patients with type 2 diabetes mellitus have great significance in decreasing the risk of diabetes-related macrovascular lesions.

[1]Adler, A.I., Stratton, I.M., Neil, H.A., Yudkin, J.S., Matthews, D.R., Cull, C.A., Wright, A.D., Turner, R.C., Holman, R.R., 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 321(7258):412-419.

[2]Aronson, D., 2008. Hyperglycemia and the Pathobiology of Diabetic Complications. In: Fisman, E.Z., Tenenbaum, A. (Eds.), Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets. Adv. Cardiol. Basel, Karger, vol.45, p.1-16.

[3]Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., Thomason, M.J., Mackness, M.I., Charlton-Menys, V., Fuller, J.H., 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364(9435):685-696.

[4]Fruchart, J.C., Sacks, F., Hermans, M.P., Assmann, G., Brown, W.V., Ceska, R., Chapman, M.J., Dodson, P.M., Fioretto, P., Ginsberg, H.N., et al., 2008. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol., 102(10 Suppl.):1K-34K.

[5]Gæde, P., Lund-Andersen, H., Parving, H.H., Pedersen, O., 2008. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med., 358(6):580-591.

[6]Grundy, S.M., Benjamin, I.J., Burke, G.L., Chait, A., Eckel, R.H., Howard, B.V., Mitch, W., Smith, S.C.Jr., Sowers, J.R., 1999. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 100(10):1134-1146.

[7]Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B.Jr., Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Smith, S.C.Jr., Stone, N.J., 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J. Am. Coll. Cardiol., 44(3):720-732.

[8]Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 359(15):1577-1589.

[9]Kanter, J.E., Johansson, F., LeBoeuf, R.C., Bornfeldt, K.E., 2007. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circul. Res., 100(6):769-781.

[10]Lorenz, M.W., von Kegler, S., Steinmetz, H., Markus, H.S., Sitzer, M., 2006. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke, 37(1):87-92.

[11]Lorenz, M.W., Markus, H.S., Bots, M.L., Rosvall, M., Sitzer, M., 2007. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 115(4):459-467.

[12]Niiranen, T., Jula, A., Kantola, I., Moilanen, L., Kahonen, M., Kesaniemi, Y.A., Nieminen, M.S., Reunanen, A., 2007. Home-measured blood pressure is more strongly associated with atherosclerosis than clinic blood pressure: the Finn-HOME Study. J. Hypert., 25(6):1225-1231.

[13]Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Brown, B.G., Ganz, P., Vogel, R.A., Crowe, T., Howard, G., Cooper, C.J., Brodie, B., et al., 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 291(9):1071-1080.

[14]Orasanu, G., Plutzky, J., 2009. The pathologic continuum of diabetic vascular disease. J. Am. Coll. Cardiol., 53(5 Suppl.):S35-S42.

[15]Ray, K.K., Seshasai, S.R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., Sattar, N., 2009. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 373(9677):1765-1772.

[16]Saydah, S.H., Fradkin, J., Cowie, C.C., 2004. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA, 291(3):335-342.

[17]Skyler, J.S., Bergenstal, R., Bonow, R.O., Buse, J., Deedwania, P., Gale, E.A.M., Howard, B.V., Kirkman, M.S., Kosiborod, M., Reaven, P., et al., 2009. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. J. Am. Coll. Cardiol., 53(3):298-304.

[18]Sowers, J.R., Bakris, G.L., 2000. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N. Engl. J. Med., 342(13):969-970.

[19]Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., Hadden, D., Turner, R.C., Holman, R.R., 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321(7258):405-412.

[20]Turner, R.C., Holman, R.R., Cull, C.A., Stratton, I.M., Matthews, D.R., Frighi, V., Manley, S.E., Neil, A., McElroy, K., Wright, D., et al., 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352(9131):837-853.

[21]Zanchetti, A., Crepaldi, G., Bond, M.G., Gallus, G.V., Veglia, F., Ventura, A., Mancia, G., Baggio, G., Sampieri, L., Rubba, P., et al., 2001. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. J. Hypert., 19(1):79-88.